Abstract
Patients with malignant tumors are often combined with dyslipidemia, and dyslipidemia is associated with both malignant tumor disease and treatment. The expert group of the Integrative Cardio-Oncology Society of China Anti-Cancer Association summarized the incidence rate and characteristics of dyslipidemia in patients with malignant tumors, and the characteristics and mechanisms of dyslipidemia induced by common antineoplastic drugs, stratified the risk of dyslipidemia in antineoplastic drugs, then formulated the principles of dyslipidemia treatment and monitoring. This consensus refers to domestic and aboard research progress, combineds with China's clinical experience to formulate the corresponding prevention and treatment of dyslipidemia. The present consensus provides practical strategies for clinicians in the management of dyslipidemia in malignant tumors and promotes the management of dyslipidemia in malignant tumors in China.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Zhonghua zhong liu za zhi [Chinese journal of oncology]
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
